Fig. 4.
Soluble CD30R evaluated in 1 μL serum of SCID mice inoculated with L540rec cells using human IL-2 receptor ELISA.
Serum was drawn from 3 control mice treated with PBS and from all mice treated with Ki-4(scFv)–ETA′ at different time points after tumor cell challenge.